Moderna stock more than doubled on Tuesday, August 19, 2026, after the biotech and its partner Merck announced that their personalized mRNA cancer vaccine succeeded in a pivotal late-stage melanoma trial. Shares of Moderna (NASDAQ: MRNA) surged as much as 144% intraday to about $154 from a prior close of $62.96, adding tens of billions of dollars in market value and lifting the company's market capitalization to roughly $61.5 billion within hours. Merck (NYSE: MRK) climbed about 6% to around $143. The catalyst: positive topline results from the Phase 3 INTerpath-001 study, in which the investigational vaccine intismeran autogene combined with Merck's blockbuster immunotherapy Keytruda significantly reduced the risk of melanoma returning or spreading compared with Keytruda alone. It is the first late-stage success ever reported for a personalized mRNA cancer vaccine, a milestone that validates years of research and reshapes the bull case for Moderna stock.
The Trial Win That Sent Moderna Stock Soaring
INTerpath-001 is a randomized, double-blind, global Phase 3 trial that enrolled 1,137 patients with high-risk (stage IIB-IV) melanoma whose tumors had been completely surgically removed. Participants were randomized 2:1 to receive intismeran autogene plus Keytruda or Keytruda alone. On Tuesday, Merck and Moderna said the combination met its primary endpoint of recurrence-free survival (RFS) and the key secondary endpoint of distant metastasis-free survival (DMFS), describing the improvements as statistically significant and clinically meaningful. The companies called it the first and only combination regimen to demonstrate such results against Keytruda alone in the adjuvant melanoma setting.
Intismeran autogene, also known as V940 or mRNA-4157, is what Moderna calls an individualized neoantigen therapy (INT). It is built from a sample of each patient's tumor and codes for up to 34 neoantigens tailored to that person's unique mutational signature, effectively training the immune system to recognize and attack cancer cells. "These first Phase 3 findings for intismeran in combination with KEYTRUDA as adjuvant therapy reinforce the promise of a more personalized approach to cancer treatment," Merck said in its announcement, adding that the companies plan to present full data at an upcoming international medical meeting and will engage with regulators on filing submissions.
From COVID Vaccine to Cancer Vaccine: The Road to INTerpath-001
The melanoma readout is the payoff of a bet Moderna placed years ago to extend its mRNA platform far beyond COVID-19. Here is how the story has unfolded:
- 2022-2023: Moderna and Merck report early Phase 2b results (KEYNOTE-942) showing the vaccine-Keytruda combination cut the risk of recurrence or death in high-risk melanoma.
- June 2026 (ASCO): Five-year Phase 2b follow-up shows a 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death versus Keytruda alone.
- July 31, 2026: Moderna reports second-quarter results, posting a narrower-than-expected loss of $1.97 per share versus the $2.03 consensus estimate.
- August 19, 2026: Merck and Moderna announce the Phase 3 INTerpath-001 trial met its RFS and DMFS endpoints, sending Moderna stock up more than 130%.
The companies are now running nine Phase 2 and Phase 3 trials across melanoma, non-small cell lung cancer, bladder cancer, and renal cell carcinoma, a pipeline that gives Moderna a second growth engine beyond its respiratory vaccine franchise.
Why Wall Street Is Split on Moderna Stock
Even after the pop, the Street's reaction is far from unanimous. Analysts polled by S&P Global carry a consensus "Hold" rating on Moderna with an average 12-month price target of $50.84, roughly 67% below Tuesday's trading price, with individual targets ranging from $25 to $79. On the day of the announcement, William Blair upgraded the stock to a Buy, while J.P. Morgan reiterated a Sell with a $40 target and Bernstein maintained a Hold with a $45 target, underscoring the wide gap between the market's enthusiasm and analyst models.
That disconnect reflects the two sides of the Moderna story. Bulls see the cancer vaccine as a potential multi-billion-dollar franchise, a personalized medicine that could be used earlier in treatment to address a disease where melanoma alone is expected to account for about 112,000 new U.S. diagnoses and more than 8,500 deaths in 2026. Bears point to the fundamentals: Moderna's revenue is still shrinking, with analysts modeling about $2.11 billion this year and a loss of $8.50 per share, improving to a projected $2.43 billion in revenue and a $4.83-per-share loss next year. The company has not yet disclosed the exact magnitude of the Phase 3 survival benefit, and regulatory approval, let alone commercial launch, is still some time away.
Where Moderna Stock Stands Now
As of Tuesday morning, Moderna was trading near $154, its highest level in more than a year and far above its 52-week low of $22.28. The stock began 2026 around $29.49 and had already more than doubled this year before the announcement; the melanoma win roughly tripled that year-to-date gain in a single session. Moderna's market value now sits near $61.5 billion, with about 399 million shares outstanding, insiders owning roughly 6.7%, and BlackRock listed as the largest institutional holder at about 7.7%.
What Happens Next for Moderna Stock
The immediate catalyst investors are watching is the full data presentation at an upcoming medical meeting, where analysts will look for the exact hazard ratios on recurrence-free and distant metastasis-free survival, safety details, and subgroup results. Beyond that, Moderna and Merck say they will engage with regulators on filing submissions for intismeran autogene in combination with Keytruda, a path that could lead to an accelerated approval filing given the strength of the Phase 2b and Phase 3 signals. Moderna CEO Stephane Bancel framed the moment in sweeping terms: "For many years, the idea of creating an mRNA treatment designed specifically for an individual patient's cancer was aspirational. We are now helping turn that vision into a reality."
Key Takeaways for Investors
- Moderna stock more than doubled on Aug. 19, 2026, after the Phase 3 INTerpath-001 melanoma trial met its primary and key secondary endpoints.
- The personalized mRNA vaccine intismeran autogene plus Keytruda reduced melanoma recurrence and spread versus Keytruda alone in 1,137 high-risk patients.
- The result is the first late-stage win for a personalized mRNA cancer vaccine, building on Phase 2b data showing a 49% reduction in recurrence-or-death risk.
- Wall Street remains cautious: the average price target is about $51 versus a share price near $154.
- Next catalysts include full data at a medical meeting and regulatory engagement for potential filings.
